Keywords: Tumors, TumorWe tested the hypothesis that autopsy-based radio-pathomic maps of glioblastoma pathology reveal distinct phenotypes (hypercellular, hypocellular, hybrid, and well-circumscribed fronts) that differ in patient survival and bevacizumab treatment response. Patients with tumor invasion beyond contrast showed worse survival outcomes compared to patients with well-circumscribed tumors. Additionally, patients with hypocellular components of the non-enhancing front selectively benefit from bevacizumab treatment, with an observable reduction in the hypocellular volume over the course of bevacizumab use.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords